Lilly's lupus loss is XTL's gain; AstraZeneca and Clovis race to the lung cancer market;

@FierceBiotech: IPO hopeful rEVO puts off its plans for a $75M debut. Item | Follow @FierceBiotech

@JohnCFierce: Interesting to see which #biotech #IPOs do well and which flop. Congrats to $DERM. | Follow @JohnCFierce

@DamianFierce: ICYMI: $LLY's bailing on tabalumab­ in lupus after two Phase III misses. Release | Follow @DamianFierce

@EmilyMFierce: Did you miss our list of notable academic-pharma alliances of 2014? Check it out here. | Follow @EmilyMFierce

> Eli Lilly's ($LLY) announcement that its late-stage tabalumab failed in lupus, boosted shares of XTL Biopharmaceuticals ($XTLB), at work on its own treatment for the disease. News

> AstraZeneca ($AZN) and Clovis Oncology ($CLVS) are racing to the FDA with drugs for treatment-resistant lung cancer, angling for position in a market expected to clock in at $3 billion a year. Story

Medical Device News

@FierceMedDev: Have you checked out our 15 most promising #medtech companies yet? Report | Follow @FierceMedDev

@VarunSaxena2: Alnylam says it wants to enter larger disease areas using partnership-driven approach. News | Follow @VarunSaxena2

@EmilyWFierce: FDA cracking down on companies marketing essential oils as treatments or cures for Ebola. More from the WSJ | Follow @EmilyWFierce

> Hopkins physician creates 3-D printed hands for pediatric patients. More

> EU regulators to conduct antitrust probe of $13.4B Zimmer/Biomet deal. Story

> Glooko enables wireless smartphone access for existing blood glucose monitors. News

Pharma News

@FiercePharma: Did you miss our latest special report yesterday? Not to worry: Top 10 pharma companies by employees - 2014. Report | Follow @FiercePharma

@CarlyHFierce: Salix drops Cosmo buy, opting to talk takeover with Actavis. More | Follow @CarlyHFierce

> Ascension hospitals bar Genentech reps after cancer drug distribution switch. Story

> NICE nixes Roche's new leukemia drug Gazyvaro despite discount offer. News

> Add Arbor Pharma to your shopping list: It's on the block for $1B-plus. Article

Suggested Articles

The data, from two patients with severe blood disorders, are "promising” for what could be a one-and-done treatment, Cantor Fitzgerald analysts wrote.

The fund will back pharma companies as well as developers of medtech products and providers of outsourced services.

The money will fund work to develop polymers in multiple indications and an associated U.S. expansion.